Matteo Brunelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4230738/publications.pdf

Version: 2024-02-01

310 papers 8,407 citations

44069 48 h-index 76900 74 g-index

312 all docs

312 docs citations

312 times ranked

9050 citing authors

#	Article	IF	Citations
1	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	2.5	390
2	Clear Cell Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2008, 32, 1239-1245.	3.7	252
3	Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Modern Pathology, 2005, 18, 161-169.	5.5	186
4	Original and reviewed nuclear grading according to the Fuhrman system. Cancer, 2005, 103, 68-75.	4.1	136
5	PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. Journal of Thoracic Oncology, 2018, 13, 1113-1120.	1.1	135
6	Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Modern Pathology, 2006, 19, 488-493.	5.5	126
7	Gains of Chromosomes 7, 17, 12, 16, and 20 and Loss of Y Occur Early in the Evolution of Papillary Renal Cell Neoplasia: A Fluorescent In Situ Hybridization Study. Modern Pathology, 2003, 16, 1053-1059.	5.5	121
8	The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, e645-e653.	1.9	115
9	Oncocytic papillary renal cell carcinoma: a clinicopathologic, immunohistochemical, ultrastructural, and interphase cytogenetic study of 12 cases. Annals of Diagnostic Pathology, 2006, 10, 133-139.	1.3	112
10	Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Modern Pathology, 2011, 24, 1313-1319.	5.5	112
11	Renal Disease in Adults With TSC2/PKD1 Contiguous Gene Syndrome. American Journal of Surgical Pathology, 2002, 26, 198-205.	3.7	105
12	Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Modern Pathology, 2012, 25, 100-111.	5.5	105
13	Parvalbumin Is Constantly Expressed in Chromophobe Renal Carcinoma. Modern Pathology, 2001, 14, 760-767.	5.5	104
14	Metanephric Adenoma Lacks the Gains of Chromosomes 7 and 17 and Loss of Y That Are Typical of Papillary Renal Cell Carcinoma and Papillary Adenoma. Modern Pathology, 2003, 16, 1060-1063.	5.5	101
15	Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/ <i>neu</i> Amplification. American Journal of Clinical Pathology, 2009, 131, 678-682.	0.7	101
16	Renal Cell Carcinomas With Papillary Architecture and Clear Cell Components. American Journal of Surgical Pathology, 2008, 32, 1780-1786.	3.7	98
17	Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Modern Pathology, 2008, 21, 1-6.	5.5	97
18	Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Modern Pathology, 2006, 19, 780-787.	5.5	92

#	Article	IF	CITATIONS
19	Molecular Genetic Evidence for the Independent Origin of Multifocal Papillary Tumors in Patients with Papillary Renal Cell Carcinomas. Clinical Cancer Research, 2005, 11, 7226-7233.	7.0	89
20	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. Oncotarget, 2017, 8, 90123-90131.	1.8	89
21	Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Modern Pathology, 2009, 22, 161-166.	5.5	88
22	Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors. European Urology, 2010, 58, 655-668.	1.9	84
23	MiT Family Translocation Renal Cell Carcinoma: from the Early Descriptions to the Current Knowledge. Cancers, 2019, 11, 1110.	3.7	79
24	Identical Allelic Losses in Mature Teratoma and Other Histologic Components of Malignant Mixed Germ Cell Tumors of the Testis. American Journal of Pathology, 2003, 163, 2477-2484.	3.8	78
25	Prognostic Role of the Histologic Subtypes of Renal Cell Carcinoma after Slide Revision. European Urology, 2006, 50, 786-794.	1.9	77
26	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non–Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. American Journal of Surgical Pathology, 2018, 42, 1384-1389.	3.7	77
27	Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors. Modern Pathology, 2004, 17, 1309-1313.	5.5	76
28	Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma. Modern Pathology, 2007, 20, 303-309.	5.5	76
29	The â€~Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancerâ€specific survival in patients with clear cell renal cell carcinoma. BJU International, 2009, 103, 165-170.	2.5	73
30	Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study. Modern Pathology, 2007, 20, 722-728.	5 . 5	72
31	Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews, 2015, 41, 767-776.	7.7	71
32	Clear Cell Papillary Renal Cell Carcinoma–like Tumors in Patients With Von Hippel-Lindau Disease Are Unrelated to Sporadic Clear Cell Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1131-1139.	3.7	70
33	CD10 is expressed in a subset of chromophobe renal cell carcinomas. Modern Pathology, 2004, 17, 1455-1463.	5.5	67
34	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Critical Reviews in Oncology/Hematology, 2015, 96, 81-90.	4.4	64
35	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treatment Reviews, 2017, 54, 68-73.	7.7	64
36	Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology, 2016, 68, 422-432.	2.9	62

#	Article	IF	Citations
37	Oncocytoma-like Angiomyolipoma. Archives of Pathology and Laboratory Medicine, 2002, 126, 610-612.	2.5	62
38	Clear cell papillary renal cell carcinoma: micro-RNA expression profiling and comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Human Pathology, 2014, 45, 1130-1138.	2.0	61
39	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences, 2021, 22, 5123.	4.1	61
40	Renal Cell Neoplasms of Oncocytosis Have Distinct Morphologic, Immunohistochemical, and Cytogenetic Profiles. American Journal of Surgical Pathology, 2010, 34, 620-626.	3.7	58
41	Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of <i>EGFR</i> mutant advanced lung adenocarcinoma. Oncotarget, 2015, 6, 12783-12795.	1.8	58
42	PEComas of the kidney and of the genitourinary tract. Seminars in Diagnostic Pathology, 2015, 32, 140-159.	1.5	56
43	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351.	3.6	56
44	Diagnostic concordance between whole slide imaging and conventional light microscopy in cytopathology: A systematic review. Cancer Cytopathology, 2020, 128, 17-28.	2.4	56
45	HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys. Oncogene, 2018, 37, 1654-1668.	5.9	55
46	Metanephric adenoma: the utility of immunohistochemical and cytogenetic analyses in differential diagnosis, including solid variant papillary renal cell carcinoma and epithelial-predominant nephroblastoma. Modern Pathology, 2015, 28, 1236-1248.	5.5	53
47	Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review. Clinical Genitourinary Cancer, 2016, 14, 117-121.	1.9	52
48	AR-V7 and prostate cancer: The watershed for treatment selection?. Cancer Treatment Reviews, 2016, 43, 27-35.	7.7	49
49	t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma. Modern Pathology, 2018, 31, 474-487.	5.5	49
50	Expression of programmed cell death ligand 1 in nonâ€"small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. Cancer Cytopathology, 2019, 127, 52-61.	2.4	49
51	HER-2/neu Assessment in Breast Cancer Using the Original FDA and New ASCO/CAP Guideline Recommendations. American Journal of Clinical Pathology, 2008, 129, 907-911.	0.7	48
52	ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung. Journal of Thoracic Oncology, 2014, 9, 729-732.	1.1	47
53	Immune checkpoint inhibitors and prostate cancer: a new frontier?. Oncology Reviews, 2016, 10, 293.	1.8	47
54	The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews, 2016, 49, 37-44.	7.7	46

#	Article	IF	CITATIONS
55	Impact of image analysis and artificial intelligence in thyroid pathology, with particular reference to cytological aspects. Cytopathology, 2020, 31, 432-444.	0.7	46
56	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. Oncologist, 2016, 21, 283-291.	3.7	45
57	Acquired cystic disease–associated renal cell carcinoma with sarcomatoid change and rhabdoid features. Annals of Diagnostic Pathology, 2011, 15, 462-466.	1.3	44
58	Aggressive and nonaggressive translocation $t(6;11)$ renal cell carcinoma: comparative study of 6 cases and review of the literature. Annals of Diagnostic Pathology, 2014, 18, 351-357.	1.3	44
59	Risk stratification and prognostication of renal cell carcinoma. World Journal of Urology, 2008, 26, 115-125.	2.2	43
60	Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. Leukemia and Lymphoma, 2014, 55, 2620-2626.	1.3	43
61	Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical, and genetic features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 193-200.	2.8	42
62	Diagnostic Usefulness of Fluorescent Cytogenetics in Differentiating Chromophobe Renal Cell Carcinoma From Renal Oncocytoma. American Journal of Clinical Pathology, 2010, 133, 116-126.	0.7	41
63	Digital reporting of whole-slide images is safe and suitable for assessing organ quality in preimplantation renal biopsies. Human Pathology, 2016, 47, 115-120.	2.0	41
64	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 2018, 70, 67-74.	7.7	41
65	Validation of Remote Digital Frozen Sections for Cancer and Transplant Intraoperative Services. Journal of Pathology Informatics, 2018, 9, 34.	1.7	41
66	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Scientific Reports, 2018, 8, 7119.	3.3	39
67	A distinctive translocation carcinoma of the kidney; "rosette forming,―t(6;11), HMB45-positive renal tumor: a histomorphologic, immunohistochemical, ultrastructural, and molecular genetic study of 4 cases. Human Pathology, 2012, 43, 726-736.	2.0	37
68	FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. Journal of Experimental and Clinical Cancer Research, 2012, 31, 103.	8.6	37
69	Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 383-387.	1.2	37
70	iPathology cockpit diagnostic station: validation according to College of American Pathologists Pathology and Laboratory Quality Center recommendation at the Hospital Trust and University of Verona. Diagnostic Pathology, 2014, 9, S12.	2.0	36
71	Prostate Volume Index and Chronic Inflammation of the Prostate Type IV with Respect to the Risk of Prostate Cancer. Urologia Internationalis, 2015, 94, 270-285.	1.3	36
72	Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects. International Journal of Molecular Sciences, 2016, 17, 735.	4.1	36

#	Article	IF	CITATIONS
73	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	3.2	36
74	Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. Journal of Personalized Medicine, 2022, 12, 1073.	2.5	36
75	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. Pathology, 2020, 52, 297-309.	0.6	35
76	Vimentin Reactivity in Renal Oncocytoma: Immunohistochemical Study of 234 Cases. Archives of Pathology and Laboratory Medicine, 2007, 131, 1782-1788.	2.5	35
77	Pre-implantation kidney biopsy: value of the expertise in determining histological score and comparison with the whole organ on a series of discarded kidneys. Journal of Nephrology, 2020, 33, 167-176.	2.0	34
78	Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma. Endocrine Pathology, 2020, 31, 291-300.	9.0	34
79	Renal cell carcinoma with smooth muscle stroma lacks chromosome 3p and VHL alterations. Modern Pathology, 2014, 27, 765-774.	5.5	32
80	Body mass index is an independent predictor of Clavien–Dindo grade 3 complications in patients undergoing robot assisted radical prostatectomy with extensive pelvic lymph node dissection. Journal of Robotic Surgery, 2019, 13, 83-89.	1.8	32
81	High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection. Asian Journal of Andrology, 2020, 22, 323.	1.6	32
82	Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. Histopathology, 2017, 71, 725-735.	2.9	31
83	Schwannoma of the Kidney. Modern Pathology, 2008, 21, 779-783.	5.5	30
84	Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis. Scientific Reports, 2017, 7, 2374.	3.3	30
85	Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. Pathology, 2017, 49, 10-18.	0.6	30
86	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. European Journal of Cancer, 2017, 83, 237-246.	2.8	30
87	Renal oncocytoma with and without intravascular extension into the branches of renal vein have the same morphological, immunohistochemical and genetic features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 285-293.	2.8	29
88	S-100A1 Is a Reliable Marker in Distinguishing Nephrogenic Adenoma From Prostatic Adenocarcinoma. American Journal of Surgical Pathology, 2009, 33, 1031-1036.	3.7	29
89	Accuracy of on-bench biopsies in the evaluation of the histological subtype, grade, and necrosis of renal tumours. Pathology, 2011, 43, 149-155.	0.6	28
90	Lymph Nodes Invasion of Marcille's Fossa Associates with High Metastatic Load in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection: The Role of "Marcillectomy― Urologia Internationalis, 2019, 103, 25-32.	1.3	28

#	Article	IF	Citations
91	PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy. Pathology Research and Practice, 2021, 226, 153605.	2.3	28
92	The Landscape of Digital Pathology in Transplantation: From the Beginning to the Virtual E-Slide. Journal of Pathology Informatics, 2019, 10, 21.	1.7	28
93	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. Journal of Experimental and Clinical Cancer Research, 2011, 30, 115.	8.6	27
94	Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder. Molecular and Clinical Oncology, 2014, 2, 575-580.	1.0	27
95	Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. Urologia Internationalis, 2018, 101, 38-46.	1.3	27
96	VEGFA amplification/increased gene copy number and VEGFA mRNA expression in renal cell carcinoma with TFEB gene alterations. Modern Pathology, 2019, 32, 258-268.	5 . 5	27
97	Extended pelvic lymphadenectomy for prostate cancer: should the Cloquet's nodes dissection be considered only an option?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 136-145.	3.9	27
98	Low-Risk Prostate Cancer and Tumor Upgrading to Higher Patterns in the Surgical Specimen. Analysis of Clinical Factors Predicting Tumor Upgrading to Higher Gleason Patterns in a Contemporary Series of Patients Who Have Been Evaluated According to the Modified Gleason Score Grading System. Urologia Internationalis, 2016, 97, 32-41.	1.3	26
99	Donorâ€Transmitted Cancers in Transplanted Livers: Analysis of Clinical Outcomes. Liver Transplantation, 2021, 27, 55-66.	2.4	26
100	TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1. Modern Pathology, 2021, 34, 842-850.	5 . 5	26
101	Evidenceâ€based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology. Cancer Cytopathology, 2022, 130, 96-109.	2.4	26
102	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. Oncotarget, 2018, 9, 30465-30471.	1.8	26
103	Interphase cytogenetic analysis with centromeric probes for chromosomes 1, 2, 6, 10, and 17 in 11 tumors from a patient with bilateral renal oncocytosis. Modern Pathology, 2008, 21, 498-504.	5 . 5	25
104	Adrenal extramedullary hematopoiesis: report on a pediatric case and update of the literature. International Urology and Nephrology, 2001, 33, 601-603.	1.4	24
105	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II \hat{l}_\pm , survivin, and E-cadherin. Human Pathology, 2016, 57, 78-84.	2.0	24
106	High Testosterone Preoperative Plasma Levels Independently Predict Biopsy Gleason Score Upgrading in Men with Prostate Cancer Undergoing Radical Prostatectomy. Urologia Internationalis, 2016, 96, 470-478.	1.3	24
107	Clinical Factors of Disease Reclassification or Progression in a Contemporary Cohort of Prostate Cancer Patients Elected to Active Surveillance. Urologia Internationalis, 2017, 98, 32-39.	1.3	24
108	Bilateral Lymph Node Micrometastases and Seminal Vesicle Invasion Associated with Same Clinical Predictors in Localized Prostate Cancer. Tumori, 2017, 103, 299-306.	1.1	24

#	Article	IF	CITATIONS
109	Challenges facing pathologists evaluating PDâ€L1 in head & neck squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2021, 50, 864-873.	2.7	24
110	Association between Basal Total Testosterone Levels and Tumor Upgrading in Low and Intermediate Risk Prostate Cancer. Urologia Internationalis, 2017, 99, 215-221.	1.3	23
111	Low-Risk Prostate Cancer and Tumor Upgrading in the Surgical Specimen: Analysis of Clinical Factors Predicting Tumor Upgrading in a Contemporary Series of Patients Who were Evaluated According to the Modified Gleason Score Grading System. Current Urology, 2017, 10, 118-125.	0.6	23
112	PD-L1 expression in non–small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Human Pathology, 2019, 90, 54-59.	2.0	23
113	Prevalence of <scp>PDâ€L1</scp> expression in head and neck squamous precancerous lesions: a systematic review and metaâ€analysis. Head and Neck, 2020, 42, 3018-3030.	2.0	23
114	Digital pathology for second opinion consultation and donor assessment during organ procurement: Review of the literature and guidance for deployment in transplant practice. Transplantation Reviews, 2020, 34, 100562.	2.9	23
115	Angiomyolipoma of the kidney: from simple hamartoma to complex tumour. Pathology, 2021, 53, 129-140.	0.6	23
116	Clinical factors stratifying the risk of tumor upgrading to high-grade disease in low-risk prostate cancer. Tumori, 2018, 104, 111-115.	1.1	22
117	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. Oncotarget, 2017, 8, 54096-54105.	1.8	22
118	Prostate-specific antigen levels and proportion of biopsy positive cores are independent predictors of upgrading patterns in low-risk prostate cancer. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 66-71.	3.9	22
119	Subepithelial Pelvic Hematoma (Antopol—Goldman Lesion) Simulating Renal Neoplasm: Report of a Case and Review of the Literature. International Journal of Surgical Pathology, 2009, 17, 264-267.	0.8	21
120	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. PLoS ONE, 2015, 10, e0127908.	2.5	21
121	Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta. Journal of Hypertension, 2016, 34, 1364-1370.	0.5	21
122	Clinical Factors Predicting and Stratifying the Risk of Lymph Node Invasion in Localized Prostate Cancer. Urologia Internationalis, 2017, 99, 207-214.	1.3	21
123	Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells $\hat{a} \in (i)$ in vitro (i) $\hat{a} \in (i)$ and correlating with progression $\hat{a} \in (i)$ in vivo (i) $\hat{a} \in (i)$ Oncotarget, 2016, 7, 74189-74202.	1.8	21
124	Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. Cancer Treatment Reviews, 2014, 40, 847-856.	7.7	20
125	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma―According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. Pathology and Oncology Research, 2018, 24, 447-456.	1.9	20
126	Risk factors of positive surgical margins after robot-assisted radical prostatectomy in high-volume center: results in 732 cases. Journal of Robotic Surgery, 2020, 14, 167-175.	1.8	20

#	Article	IF	Citations
127	Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumors. Cell Death and Disease, 2020, 11, 1039.	6.3	20
128	Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 680973.	4.8	20
129	Percutaneous renal tumour biopsy. Histopathology, 2014, 65, 295-308.	2.9	19
130	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	7.7	19
131	Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization–based assay: Cytological smears versus cell blocks. Cancer Cytopathology, 2017, 125, 303-312.	2.4	19
132	Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. Oncotarget, 2017, 8, 7328-7335.	1.8	19
133	Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 13-20.	2.8	19
134	TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. Modern Pathology, 2022, 35, 376-385.	5.5	19
135	Cathepsin K: A Novel Diagnostic and Predictive Biomarker for Renal Tumors. Cancers, 2021, 13, 2441.	3.7	19
136	Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors. Journal of Thoracic Oncology, 2015, 10, 1341-1348.	1.1	18
137	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. Targeted Oncology, 2018, 13, 649-655.	3.6	18
138	How safe are organs from deceased donors with neoplasia? The results of the Italian Transplantation Network. Journal of Nephrology, 2019, 32, 323-330.	2.0	18
139	Is a Drain Needed After Robotic Radical Prostatectomy With or Without Pelvic Lymph Node Dissection? Results of a Single-Center Randomized Clinical Trial. Journal of Endourology, 2021, 35, 922-928.	2.1	18
140	Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples. Journal of Clinical Pathology, 2020, 73, 96-101.	2.0	18
141	PDâ€L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside. Clinical and Experimental Dental Research, 2022, 8, 690-698.	1.9	18
142	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 70, 112-117.	7.7	17
143	Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A â€~Hard Days Night'. Current Pharmaceutical Design, 2014, 20, 3958-3972.	1.9	17
144	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand? Future Oncology, 2015, 11, 107-119.	2.4	16

#	Article	IF	CITATIONS
145	Robotic assisted radical prostatectomy accelerates postoperative stress recovery: Final results of a contemporary prospective study assessing pathophysiology of cortisol peri-operative kinetics in prostate cancer surgery. Asian Journal of Urology, 2016, 3, 88-95.	1.2	16
146	Prognostic impact of proliferation for resected early stage †pure†invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. Breast, 2017, 35, 21-26.	2.2	16
147	Virtual autopsy as a screening test before traditional autopsy: The verona experience on 25 Cases. Journal of Pathology Informatics, 2018, 9, 28.	1.7	16
148	Many facets of chromosome 3p cytogenetic findings in clear cell renal carcinoma: the need for agreement in assessment FISH analysis to avoid diagnostic errors. Histology and Histopathology, 2011, 26, 1207-13.	0.7	16
149	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. Targeted Oncology, 2016, 11, 569-577.	3.6	15
150	Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials. Cancer Treatment Reviews, 2015, 41, 262-270.	7.7	14
151	The route to personalized medicine in bladder cancer: where do we stand?. Targeted Oncology, 2015, 10, 325-336.	3.6	14
152	Primary seminal vesicle carcinoma. The usefulness of PAX8 immunohistochemical expression for the differential diagnosis. Human Pathology, 2017, 69, 123-128.	2.0	14
153	Inverse Association of Prostatic Chronic Inflammation among Prostate Cancer Tumor Grade Groups: Retrospective Study of 738 Consecutive Cases Elected to a First Random Biopsy Set. Urologia Internationalis, 2018, 100, 456-462.	1.3	14
154	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Seminars in Oncology, 2019, 46, 65-72.	2.2	14
155	The impact of extended pelvic lymph node dissection on the risk of hospital readmission within 180Âdays after robot assisted radical prostatectomy. World Journal of Urology, 2020, 38, 2799-2809.	2.2	14
156	Primary pleomorphic rhabdomyosarcoma of the kidney in an adult. Annals of Diagnostic Pathology, 2008, 12, 301-303.	1.3	13
157	Robotic-assisted radical prostatectomy is less stressful than the open approach: results of a contemporary prospective study evaluating pathophysiology of cortisol stress-related kinetics in prostate cancer surgery. Journal of Robotic Surgery, 2015, 9, 249-255.	1.8	13
158	RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes. BMC Cancer, 2016, 16, 11.	2.6	13
159	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. Experimental and Molecular Pathology, 2017, 102, 276-279.	2.1	13
160	Rapid screening for malignancy in organ donors: 15â€year experience with the Verona "Alert―protocol and review of the literature. Clinical Transplantation, 2017, 31, e13045.	1.6	13
161	Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection. International Urology and Nephrology, 2020, 52, 2097-2105.	1.4	13
162	Endogenous testosterone as a predictor of prostate growing disorders in the aging male. International Urology and Nephrology, 2021, 53, 843-854.	1.4	13

#	Article	IF	CITATIONS
163	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget, 2018, 9, 29753-29771.	1.8	13
164	Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 516-523.	3.9	13
165	Impact of mobile devices on cancer diagnosis in cytology. Diagnostic Cytopathology, 2022, 50, 34-45.	1.0	13
166	Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles. Expert Opinion on Therapeutic Targets, 2021, 25, 1095-1105.	3.4	13
167	True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs. PLoS ONE, 2012, 7, e49689.	2.5	12
168	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2014, 90, 135-145.	4.4	12
169	P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas. Modern Pathology, 2014, 27, 204-213.	5.5	12
170	Cathepsin K expression in clear cell "sugar―tumor (PEComa) of the lung. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 55-59.	2.8	12
171	Serum testosterone and obesity in prostate cancer biology: a call for health promotion in the ageing male. Aging Clinical and Experimental Research, 2021, 33, 1399-1401.	2.9	12
172	H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 987-996.	2.8	12
173	A Re-Emerging Marker for Prognosis in Hepatocellular Carcinoma: The Add-Value of FISHing c-myc Gene for Early Relapse. PLoS ONE, 2013, 8, e68203.	2.5	12
174	Classical lobular breast carcinoma consistently lacks <i>topoisomeraseâ€IIα</i> gene amplification: implications for the tailored use of anthracyclineâ€based chemotherapies. Histopathology, 2012, 60, 482-488.	2.9	11
175	Comparison Between Invasive Breast Cancer With Extensive Peritumoral Vascular Invasion and Inflammatory Breast Carcinoma. American Journal of Clinical Pathology, 2014, 142, 299-306.	0.7	11
176	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. Immunotherapy, 2017, 9, 579-587.	2.0	11
177	Positive Association between Basal Total Testosterone Circulating Levels and Tumor Grade Groups at the Time of Diagnosis of Prostate Cancer. Urologia Internationalis, 2019, 103, 400-407.	1.3	11
178	Prostate volume index and prostatic chronic inflammation predicted low tumor load in 945 patients at baseline prostate biopsy. World Journal of Urology, 2020, 38, 957-964.	2.2	11
179	Linear extent of positive surgical margin impacts biochemical recurrence after robot-assisted radical prostatectomy in a high-volume center. Journal of Robotic Surgery, 2020, 14, 663-675.	1.8	11
180	TRPM8 protein expression in hormone na \tilde{A} ve local and lymph node metastatic prostate cancer. Pathologica, 2021, 113, 95-101.	3.4	11

#	Article	IF	CITATIONS
181	Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a & Does that Represe	1.7	11
182	Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability. Frontiers in Medicine, 2022, 9, 874213.	2.6	11
183	Periorbital Subcutaneous Tumor-Like Lesion Due to Dirofilaria repens. International Journal of Surgical Pathology, 2008, 16, 101-103.	0.8	10
184	Prostate Volume Index Associates with a Decreased Risk of Prostate Cancer: Results of a Large Cohort of Patients Elected to a First Biopsy Set. Urologia Internationalis, 2017, 98, 22-27.	1.3	10
185	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. European Urology Supplements, 2017, 16, 309-315.	0.1	10
186	Intraprostatic Chronic Inflammation is Associated with a Reduced Risk of Prostate Cancer in Patients Elected to a First Random Biopsy Set. Tumori, 2017, 103, 475-482.	1.1	10
187	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. International Journal of Biological Markers, 2017, 32, 243-247.	1.8	10
188	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 526.e13-526.e18.	1.6	10
189	PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. Journal of Immunotherapy, 2019, 42, 269-273.	2.4	10
190	Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091530.	3.2	10
191	Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection. International Urology and Nephrology, 2021, 53, 2027-2039.	1.4	10
192	Endogenous testosterone mirrors prostate cancer aggressiveness: correlation between basal testosterone serum levels and prostate cancer European Urology Association clinical risk classes in a large cohort of Caucasian patients. International Urology and Nephrology, 2020, 52, 1261-1269.	1.4	10
193	Herâ€2/neu evaluation in Sister Mary Joseph's nodule from breast carcinoma: a case report and review of the literature. Journal of Cutaneous Pathology, 2009, 36, 702-705.	1.3	9
194	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. Breast, 2016, 29, 24-30.	2.2	9
195	Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy. Current Urology, 2016, 9, 82-92.	0.6	9
196	Mesothelial/monocytic incidental cardiac excrescences (MICE): report of a case and review of literature with focus on pathogenesis. Cardiovascular Pathology, 2018, 36, 25-29.	1.6	9
197	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. Molecular Diagnosis and Therapy, 2019, 23, 569-577.	3.8	9
198	Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy. International Urology and Nephrology, 2019, 51, 2169-2180.	1.4	9

#	Article	IF	CITATIONS
199	Liver Metastases From Renal Oncocytoma With Vascular Extension. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, e48-e53.	1.2	9
200	Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study. Infectious Agents and Cancer, 2021, 16, 22.	2.6	9
201	Open approach, extended pelvic lymph node dissection, and seminal vesicle invasion are independent predictors of hospital readmission after prostate cancer surgery: a large retrospective study. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 72-81.	3.9	9
202	Chondroid Syringoma With Extensive Ossification. International Journal of Surgical Pathology, 2007, 15, 385-387.	0.8	8
203	Bladder Perivascular Epithelioid Cell Tumor (PEComa): A Case Report and Literature Review. Urologia, 2015, 82, 120-123.	0.7	8
204	Break–apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET/PTC rearrangements. European Journal of Endocrinology, 2015, 172, 571-582.	3.7	8
205	High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Modern Pathology, 2016, 29, 1347-1357.	5 . 5	8
206	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 39-43.	1.2	8
207	Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm. Biomarkers, 2018, 23, 305-314.	1.9	8
208	Renal cell carcinoma in one year: Going inside the news of 2017 – A report of the main advances in RCC cancer research. Cancer Treatment Reviews, 2018, 67, 29-33.	7.7	8
209	High surgeon volume and positive surgical margins can predict the risk of biochemical recurrence after robot-assisted radical prostatectomy. Therapeutic Advances in Urology, 2019, 11, 175628721987828.	2.0	8
210	Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease. Urologia Internationalis, 2019, 103, 391-399.	1.3	8
211	Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. Cancers, 2021, 13, 5517.	3.7	8
212	Technical and Diagnostic Issues in Whole Slide Imaging Published Validation Studies. Frontiers in Oncology, 0, 12, .	2.8	8
213	Neoadjuvant Strategies for Triple Negative Breast Cancer: â€~State-of-the-art' and Future Perspectives. Anti-Cancer Agents in Medicinal Chemistry, 2014, 15, 15-25.	1.7	7
214	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: â€~Game Over'?. Targeted Oncology, 2016, 11, 431-446.	3.6	7
215	Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values & Amp; #x3c; 10 ng/mL: Results of 564 Biopsy NaĀ ve Cases. Urologia Internationalis, 2019, 103, 415-422.	1.3	7
216	Management of Thyroid Nodules in Deceased Donors With Comparison Between Fine Needle Aspiration and Intraoperative Frozen Section in the Setting of Transplantation. Progress in Transplantation, 2019, 29, 316-320.	0.7	7

#	Article	IF	Citations
217	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. Journal of Clinical Pathology, 2022, 75, 39-44.	2.0	7
218	Stimulator of interferon genes (STING) immunohistochemical expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Pathology, 2021, 53, 579-585.	0.6	7
219	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. Current Drug Metabolism, 2017, 18, 692-699.	1.2	7
220	Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 872-886.	1.7	7
221	Suitability of infiltrative lobular breast carcinoma for antiâ€human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting. Histopathology, 2010, 57, 935-940.	2.9	6
222	Utility of racemase and other immunomarkers in the detection of adenocarcinoma in prostatic tissue damaged by high intensity focused ultrasound therapy. Pathology, 2010, 42, 1-5.	0.6	6
223	PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. Expert Opinion on Pharmacotherapy, 2013, 14, 597-608.	1.8	6
224	Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study. Asian Journal of Urology, 2015, 2, 224-232.	1.2	6
225	Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification asÂPredictors of Pathologic Complete Response toÂNeoadjuvant Chemotherapy With Trastuzumab and Docetaxel. Clinical Breast Cancer. 2015. 15. 16-23.	2.4	6
226	Prostate Volume Index Stratified Prostate Cancer Risk in Patients Elected to a First Random Biopsy Set. Tumori, 2017, 103, 374-379.	1.1	6
227	Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients. Current Urology, 2017, 10, 72-80.	0.6	6
228	Proximal CD13 Versus Distal GATA-3 Expression in Renal Neoplasia According to WHO 2016 Classification. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 316-323.	1.2	6
229	Surgeon volume and body mass index influence positive surgical margin risk after robot-assisted radical prostatectomy: Results in 732 cases. Arab Journal of Urology Arab Association of Urology, 2019, 17, 234-242.	1.5	6
230	Histopathology and Long-Term Outcome of Kidneys Transplanted From Donors With Severe Acute Kidney Injury. Progress in Transplantation, 2019, 29, 36-42.	0.7	6
231	Predictors of complications occurring after open and robot-assisted prostate cancer surgery: a retrospective evaluation of 1062 consecutive patients treated in a tertiary referral high volume center. Journal of Robotic Surgery, 2022, 16, 45-52.	1.8	6
232	Donor kidneys with miliary papillary renal cell neoplasia: The role of the pathologist in determining suitability for transplantation. Annals of Transplantation, 2014, 19, 362-366.	0.9	6
233	De Novo Renal Neoplasia After Kidney Transplantation According to New 2016 WHO Classification of Renal Tumors. Annals of Transplantation, 2016, 21, 745-754.	0.9	6
234	Adenocarcinoma of the paraurethral glands: a case report. Histology and Histopathology, 2014, 29, 1295-303.	0.7	6

#	Article	IF	Citations
235	Adult primary teratoma of the testisreport on 5 cases in clinical stage I disease. International Urology and Nephrology, 2001, 33, 657-659.	1.4	5
236	Primary bi-atrial Burkitt lymphoma with severe inflow impairment in an immunocompetent patient. Cardiovascular Pathology, 2009, 18, 123-125.	1.6	5
237	Tertiary Gleason pattern 5 on needle biopsy predicts greater tumour volume on radical prostatectomy. Pathology, 2011, 43, 693-696.	0.6	5
238	Pediatric Optic Nerve Sheath Meningioma. Journal of Neuro-Ophthalmology, 2014, 34, 315-316.	0.8	5
239	Associations of Transitional Zone Volume with Intraprostatic Chronic Inflammation and Prostate Cancer Risk in Patients Undergoing a First Random Biopsy Set. Current Urology, 2018, 11, 85-91.	0.6	5
240	Cortical Expression of the Polysialylated Isoform of the Neural Cell Adhesion Molecule on Brain Tissue to Recognize Drug-Related Death. American Journal of Forensic Medicine and Pathology, 2018, 39, 8-13.	0.8	5
241	Prostate volume index and prostatic chronic inflammation have an effect on tumor load at baseline random biopsies in patients with normal DRE and PSA values less than 10 ng/ml: results of 564 consecutive cases. Therapeutic Advances in Urology, 2019, 11, 175628721986860.	2.0	5
242	Cytokine-, Neurotrophin-, and Motor Rehabilitation-Induced Plasticity in Parkinson's Disease. Neural Plasticity, 2020, 2020, 1-15.	2.2	5
243	Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. Diagnostics, 2020, 10, 123.	2.6	5
244	Multifocal Hepatic Angiosarcoma with Atypical Presentation: Case Report and Literature Review. Journal of Gastrointestinal Cancer, 2021, 52, 771-775.	1.3	5
245	The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection. Urologia Internationalis, 2021, 105, 826-834.	1.3	5
246	Acute kidney injury strongly influences renal function after radical nephroureterectomy for upper tract urothelial carcinoma: A single-centre experience. Archivio Italiano Di Urologia Andrologia, 2021, 93, 9-14.	0.8	5
247	Incidental prostate cancer after transurethral resection of the prostate: analysis of incidence and risk factors in 458 patients. Minerva Urology and Nephrology, 2021, 73, 471-480.	2.5	5
248	HLA-G expression in melanomas. International Reviews of Immunology, 2021, 40, 330-343.	3.3	5
249	Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy, 2022, 14, 145-153.	2.0	5
250	The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1563-1568.	2.5	4
251	Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. Pathology, 2014, 46, 523-526.	0.6	4
252	Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage †pure†and †mixed†lobular breast cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 50.	8.6	4

#	Article	IF	CITATIONS
253	ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes. Cancer Biomarkers, 2017, 18, 215-220.	1.7	4
254	Autophagy pathways in drug abusers after forensic autopsy: LC3B, ph-mTOR and p70S6K analysis. Medicine, Science and the Law, 2019, 59, 49-56.	1.0	4
255	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. Breast, 2020, 50, 56-63.	2.2	4
256	Parvalbumin immunohistochemical expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 785-791.	2.8	4
257	Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity. Urologia Internationalis, 2021, 105, 362-369.	1.3	4
258	Pulmonary Fat Embolism and Coronary Amyloidosis. American Journal of Case Reports, 2018, 19, 744-747.	0.8	4
259	Innovation in Transplantation: The Digital Era. Journal of Pathology Informatics, 2018, 9, 33.	1.7	4
260	Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer. International Urology and Nephrology, 2021, 53, 2505-2515.	1.4	4
261	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. American Journal of Cancer Research, 2014, 4, 907-15.	1.4	4
262	Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection. International Urology and Nephrology, 2022, 54, 541-550.	1.4	4
263	Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer. Tumori, 2018, 104, 307-311.	1.1	3
264	Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report. Oncology Letters, 2018, 17, 462-467.	1.8	3
265	Keratocystoma of the parotid gland is rare and requires an integrated multidisciplinary approach: Report of a case and a literature review. Diagnostic Cytopathology, 2019, 47, 614-616.	1.0	3
266	Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors. Arab Journal of Urology Arab Association of Urology, 2020, 18, 148-154.	1.5	3
267	Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy. Therapeutic Advances in Urology, 2020, 12, 175628722092948.	2.0	3
268	Severe intraoperative bleeding predicts the risk of perioperative blood transfusion after robot-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, 16, 463-471.	1.8	3
269	Endogenous testosterone density predicts unfavorable disease at final pathology in intermediate risk prostate cancer. International Urology and Nephrology, 2021, 53, 2517-2526.	1.4	3
270	Thyroid Fine-Needle Aspiration Cytology: Focusing on Adherence to Guidelines and Hospital Organization. American Journal of Case Reports, 2020, 21, e920933.	0.8	3

#	Article	IF	CITATIONS
271	FISH scoring on paraffin sections versus single-cell suspension for chromophobe renal carcinoma and renal oncocytoma. Anticancer Research, 2011, 31, 3137-42.	1.1	3
272	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Journal of Personalized Medicine, 2022, 12, 727.	2.5	3
273	Rare case of intra-testicular adenomatoid tumour. Archivio Italiano Di Urologia Andrologia, 2014, 86, 44.	0.8	2
274	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. Future Science OA, 2015, 1, FSO29.	1.9	2
275	The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy. Archivio Italiano Di Urologia Andrologia, 2016, 88, 17.	0.8	2
276	The role of precision medicine for the treatment of metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development, 2016, 1, 369-377.	0.7	2
277	Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors. Cancer Genetics, 2017, 210, 28-33.	0.4	2
278	Clinical Factors Predicting Tumour Upgrading in Patients Under Active Surveillance and Elected to Active Treatment after Disease Reclassification or Progression. Urologia Internationalis, 2017, 99, 186-193.	1.3	2
279	Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer. Current Urology, 2017, 10, 174-181.	0.6	2
280	Predicting progression in T1 nonâ€muscleâ€invasive bladder cancer: back to histology. BJU International, 2018, 122, 914-915.	2.5	2
281	Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes. Urologia Internationalis, 2020, 104, 716-723.	1.3	2
282	Consultation between forensic and clinical pathologists for histopathology examination after forensic autopsy. Medicine, Science and the Law, 2021, 61, 25-35.	1.0	2
283	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. Expert Review of Molecular Diagnostics, 2021, 21, 161-173.	3.1	2
284	High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 565-573.	2.8	2
285	Renal tumors., 2007,, 1-1.		2
286	The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Urologia Internationalis, 2022, 106, 928-939.	1.3	2
287	HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. Anticancer Research, 2013, 33, 3705-10.	1.1	2
288	First line avelumab in PD-L1+ve metastatic or locally advanced urothelial cancer (aUC) patients unfit for cisplatin (cis): The ARIES trial Journal of Clinical Oncology, 2022, 40, 439-439.	1.6	2

#	Article	IF	Citations
289	Risk factors of extraneural spreading in astrocytomas and oligodendrogliomas in donors with gliomas: A systematic review. World Journal of Transplantation, 2022, 12, 131-141.	1.6	2
290	American Society of Anesthesiologists' (ASA) Physical Status System and Risk of Major Clavien-Dindo Complications After Robot-Assisted Radical Prostatectomy at Hospital Discharge: Analysis of 1143 Consecutive Prostate Cancer Patients. Indian Journal of Surgical Oncology, 2022, 13, 848-857.	0.7	2
291	Molecular diagnosis of renal cell neoplasms: the usefulness of immunohistochemistry and fluorescence <i>in situ</i> hybridization. Expert Opinion on Medical Diagnostics, 2008, 2, 665-676.	1.6	1
292	A novel oncocytoid papillary renal cell carcinoma, type 2, with aberrant cytogenetic abnormalities: oncocytic papillary renal cell carcinoma?. Pathology, 2013, 45, 441.	0.6	1
293	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. Anti-Cancer Drugs, 2015, 26, 469-473.	1.4	1
294	Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour) Tj ETQqQ) O O11g/BT /	Overlock 10 ⁻
295	ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance. Pathology Research and Practice, 2018, 214, 1675-1680.	2.3	1
296	From fineâ€needle aspiration cytology to fluorescent inâ€situ hybridization in an unusual case of pharyngeal synovial sarcoma. Diagnostic Cytopathology, 2019, 47, 1067-1071.	1.0	1
297	Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer. Current Urology, 2019, 12, 216-222.	0.6	1
298	Clinical-Pathological, Immunohistochemical, and Genetic Characterization of a Series of Posterior Pituitary Tumors. Journal of Neuropathology and Experimental Neurology, 2021, 80, 45-51.	1.7	1
299	Sudden death in a 39-year-old woman due to three-vessel coronary artery disease: A case report and literature review. Medicine, Science and the Law, 2021, 61, 150-154.	1.0	1
300	ABO blood group system and risk of positive surgical margins in patients treated with robot-assisted radical prostatectomy: results in 1114 consecutive patients. Journal of Robotic Surgery, 2021, , 1.	1.8	1
301	Next-generation targeted sequencing (NGTS) investigating CDK4 as a prognostic driver in pure invasive lobular breast carcinoma (ILC): Preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model Journal of Clinical Oncology, 2018, 36, 542-542.	1.6	1
302	Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2020, 46, 546-556.	1.5	1
303	Epithelioid angiomyolipoma: a pathological entity discovered in Verona with the endorsement of Doctor Rosai. Pathologica, 2021, 113, 307-315.	3.4	1
304	Utility of tissue microarrays for assessment of chromosomal abnormalities in chromophobe renal cell carcinoma., 2009, 31, 401-9.		1
305	Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors Journal of Clinical Oncology, 2014, 32, 480-480.	1.6	0
306	Prognostic value of <i>ALK</i> gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts) Journal of Clinical Oncology, 2014, 32, e19059-e19059.	1.6	0

#	ARTICLE	IF	CITATIONS
307	Ki67/MART1 and p63/SOX10 dual immunohistochemistry allows a correct interpretation of the melanocytic component in the diagnosis of pigmented pilomatricoma. Indian Journal of Dermatology, 2021, 66, 525.	0.3	0
308	Report of two primary renal tumors with myxoid features. Differential diagnosis between benign and malignant entities. Pathologica, 2021, 113, 427-435.	3.4	0
309	Value of a Multidisciplinary Approach in Sinonasal Inverted Papilloma with Extensive Ossification. American Journal of Case Reports, 2022, 23, e934149.	0.8	O
310	A fatal case of spleen rupture secondary to thrombosed aneurysm of the splenic vein. Australian Journal of Forensic Sciences, 0, , 1-10.	1.2	0